Home/StrideBio/Sapan Shah, Ph.D.

SS

Sapan Shah, Ph.D.

Chief Executive Officer

Therapeutic Areas

Neurology Cardiovascular Metabolic Genetic Disorders

StrideBio Pipeline

Drug	Indication	Phase
STRX-110	SLC13A5 Deficiency (pediatric epilepsy)	Phase 1/2
Friedreich's Ataxia Program	Friedreich's Ataxia	Preclinical
Cardiovascular Program	Undisclosed Genetic Cardiovascular Disease	Preclinical

Leadership Team at StrideBio

Aravind Asokan, Ph.D.

Founder & Chief Scientific Advisor

Patricia Zilliox, Ph.D.

Chief Development Officer

Cynthia Dunbar, M.D.

Chief Medical Officer

View full StrideBio profile